Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
Commentary|Articles|August 27, 2026
Reading CKM Signals Together: A Pharmacist's Guide
Fact checked by: Ron Panarotti
Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.
Advertisement
Advertisement
In an interview with Pharmacy Times, Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA, FCCP, senior scientific director and learning consultant at the National Kidney Foundation (NKF), discussed how the cardiovascular-kidney-metabolic (CKM) syndrome framework helps pharmacists evaluate patients comprehensively. The discussion was based on his presentation at the 2026 Association of Diabetes Care and Education Specialists (ADCES) Annual Conference in Columbus, Ohio.
Related to this article
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Advertisement
Advertisement